A client with a dual diagnosis of Opioid Use Disorder (OUD) and Major Depressive Disorder (MDD) is being treated with buprenorphine. The client reports a significant reduction in both cravings and depressive symptoms. Which pharmacological property of buprenorphine is most likely contributing to the antidepressant effect?
-
A
Partial agonism at mu-opioid receptors
-
B
Antagonism at kappa-opioid receptors
-
C
Full agonism at delta-opioid receptors
-
D
Blockade of serotonin reuptake